Compumedics Limited (ASX:CMP)

-5.17% (1Y)

Market Cap	52.81M
Revenue (ttm)	47.37M
Net Income (ttm)	-1.59M
Shares Out	192.04M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	27.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,309
Average Volume	20,051
Open	0.2750
Previous Close	0.2700
Day's Range	0.2750 - 0.2750
52-Week Range	0.2450 - 0.3650
Beta	0.52
RSI	45.53
Earnings Date	May 29, 2025

About Compumedics

Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the United States, and Europe. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients’ physiological data; Somté PSG; Okti; Grael PSG; Grael 4K PSG; Falcon PSG; Falcon HST; Somté, an investigative tool; Siesta 802; and Somté PSG. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's hom...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1987
• Employees: 155
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CMP

Financial Performance

In 2024, Compumedics's revenue was 50.26 million, an increase of 17.10% compared to the previous year's 42.92 million. Losses were -338,000, -94.48% less than in 2023.